Other OTC - Delayed Quote • USD
Synairgen plc (SYGGF)
At close: April 19 at 2:43 PM EDT
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Richard Marsden | CEO, MD & Executive Director | 408.42k | -- | 1967 |
| Prof. Stephen T. Holgate CBE, M.D. | Co-Founder, Non-Executive Director & Member of Scientific Advisory Board | 54.79k | -- | 1947 |
| Dr. Phillip David Monk | Chairman of Scientific Advisory Board, Chief Scientific Officer & Executive Director | 298.85k | -- | 1969 |
| Prof. Donna Davies | Co-Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Prof. Ratko Djukanovic | Co-Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Mr. Joseph Tregonning Colliver F.C.A. | CFO & Executive Director | -- | -- | 1980 |
| Dr. Gareth E. Walters Ph.D. | Chief Regulatory Officer | -- | -- | 1959 |
| Ms. Jody Brookes | Senior VP & Head of Clinical Operations | -- | -- | -- |
| Mr. Richard Francis | Senior VP and Head of CMC & Quality | -- | -- | -- |
| Dr. Victoria Tear | Head of Laboratory | -- | -- | -- |
Synairgen plc
Mailpoint 810
Level F, South Block Southampton General Hospital Tremona Road
Southampton, SO16 6YD
United Kingdom
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 34
Description
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Corporate Governance
Synairgen plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
Recent Events Information Not Available
Upcoming Events
Upcoming Events Information Not Available